ライフサイエンスコーパス: protease-activated receptor

1 redefines the concept of what constitutes a protease-activated receptor.

2 endothelial cell protein C receptor but not protease activated receptors.

3 and thus is independent of interaction with protease-activated receptors.

4 , neurogenesis and brain repair were lost in protease activated receptor 1 (PAR1) deficient mice.

5 Protease activated receptor 1 (PAR1) signaling can play

6 et age (IPF, FSC) and activation through the protease activated receptor 1 (PAR1) thrombin receptor (

7 us-encoded glycoprotein C (gC) can stimulate protease activated receptor 1 (PAR1)-enhanced infection

8 rmeability induced by the thrombin receptor, protease activated receptor 1 (PAR1).

9 he endothelial protein C receptor (EPCR) and protease activated receptor 1 (PAR1).

10 nced signaling through the G-protein coupled protease activated receptor 1 (PAR1).

11 nt to the blood via two pathways mediated by protease activated receptor 1 (PAR1).

12 Zn(2+) enhanced APC-mediated activation of protease activated receptor 1 and p44/42 MAPK.

13 viously demonstrated that the stimulation of protease activated receptor 1 promotes alphavbeta6 integ

14 g to several Gq-coupled receptors, including protease activated receptor 1, muscarinic acetylcholine

15 dependent stimulation of the MAPK pathway by protease activated receptor 1.

16 ing activities mediated by the activation of protease-activated receptor 1 (F2R, also known as PAR1)

17 FLD, we tested whether the thrombin receptor protease-activated receptor 1 (PAR-1) and hematopoietic

18 previously reported that thrombin activates protease-activated receptor 1 (PAR-1) and induces a myof

19 epidermal growth factor receptor (EGFR) and protease-activated receptor 1 (PAR-1) in endothelial cel

20 Protease-activated receptor 1 (PAR-1) mediates thrombin

21 ion of thrombin is mediated by activation of protease-activated receptor 1 (PAR-1).

22 Activation of protease-activated receptor 1 (PAR1) by activated protei

23 -1 has been shown to cleave and activate the protease-activated receptor 1 (PAR1) in noncardiac cells

24 Protease-activated receptor 1 (PAR1) is a G protein-coup

25 Protease-activated receptor 1 (PAR1) is a G protein-coup

26 The G-protein coupled, protease-activated receptor 1 (PAR1) is a membrane prote

27 Protease-activated receptor 1 (PAR1) is a thrombin-activ

28 The G protein-coupled protease-activated receptor 1 (PAR1) is irreversibly pro

29 Protease-activated receptor 1 (PAR1) is the prototypical

30 onstrate a novel signaling mechanism whereby protease-activated receptor 1 (PAR1) mediates expression

31 they disrupt signaling through the platelet protease-activated receptor 1 (PAR1) receptor.

32 using variants of human APC with or without protease-activated receptor 1 (PAR1) signaling function

33 of thrombin, and is associated with altered protease-activated receptor 1 (PAR1) signaling, as PAR1

34 Here we show that protease-activated receptor 1 (PAR1) signalling sustains

35 t protease that initiates cell signaling via protease-activated receptor 1 (PAR1) to regulate vascula

36 We previously showed that protease-activated receptor 1 (PAR1), a G protein-couple

37 Protease-activated receptor 1 (PAR1), a G-protein couple

38 by cleaving its G-protein-coupled receptors, protease-activated receptor 1 (PAR1), PAR4, or both.

39 CFs express 190 GPCRs and that activation of protease-activated receptor 1 (PAR1), the most highly ex

40 othelial cytoprotective actions that require protease-activated receptor 1 (PAR1), whereas thrombin a

41 coagulation cascade and a potent trigger of protease-activated receptor 1 (PAR1)-mediated platelet a

42 ated through G(i)-coupled receptors, such as protease-activated receptor 1 and CXC chemokine receptor

43 otease-activated receptor 4, and between rat protease-activated receptor 1 and protease-activated rec

44 d receptor 4 in human podocytes, and between protease-activated receptor 1 and protease-activated rec

45 larization and neurogenesis were mediated by protease-activated receptor 1 and were independent of th

46 These data show promise for protease-activated receptor 1 antagonism in patients und

47 population with symptomatic PAD and whether protease-activated receptor 1 antagonism with vorapaxar

48 gonising thrombin-mediated activation of the protease-activated receptor 1 on human platelets.

49 tory of myocardial infarction, inhibition of protease-activated receptor 1 with vorapaxar reduces the

50 Vorapaxar antagonizes protease-activated receptor 1, the primary receptor for

51 Mouse embryos lacking protease-activated receptors 1 and 2 showed defective hi

52 tion by thrombin and tryptase is mediated by protease-activated receptors 1 and 2, respectively.

53 s and gene expression profiles by activating protease-activated receptors 1 and 3.

54 an platelets express two thrombin receptors, protease-activated receptors 1 and 4 (PAR1 and PAR4) and

55 activates platelets by binding and cleaving protease-activated receptors 1 and 4 (PAR1 and PAR4).

56 telets revealed that DXA3 formation requires protease-activated receptors 1 and 4, cytosolic phosphol

57 Vorapaxar is a new oral protease-activated-receptor 1 (PAR-1) antagonist that in

58 actor (TF)-dependent thrombin generation and protease activated receptor-1 (PAR-1) activation contrib

59 hrombin generation and the thrombin receptor protease activated receptor-1 (PAR-1) contribute to live

60 Protease activated receptor-1 (PAR-1) is activated by MM

61 The thrombin receptor protease activated receptor-1 (PAR-1) is overexpressed i

62 to generate sickle mice deficient in either protease activated receptor-1 (PAR-1) or protease activa

63 MMP-1 proteolytically activates protease activated receptor-1 (PAR-1), a thrombin recept

64 is response was dependent upon activation of protease activated receptor-1 (PAR-1).

65 Protease activated receptor-1 (PAR1) activation by throm

66 R on endothelial cells, activates endogenous protease activated receptor-1 (PAR1) and induces PAR1-me

67 pose that APC-mediated signaling through the protease activated receptor-1 (PAR1) can favorably regul

68 enase and activator of the G protein-coupled protease activated receptor-1 (PAR1), is an emerging new

69 toprotective signaling through activation of protease activated receptor-1 (PAR1).

70 l cell protein C receptor (EPCR, PROCR), and protease activated receptor-1 (PAR1, F2R) on the growth

71 Deficiency in the thrombin receptor protease activated receptor-1 reduces hepatic inflammati

72 fferences at the transcript level, including protease activated receptor-1, protease activated recept

73 Protease activated receptor-1, the presumptive thrombin

74 by proteolytic cleavage on activation of the protease activated receptor-1, with antiangiogenic prope

75 own for epidermal growth factor receptor and protease activated receptor-1.

76 Protease-activated receptor-1 (PAR(1)) is a G-protein-co

77 eruli, aPC preserves endothelial cells via a protease-activated receptor-1 (PAR-1) and endothelial pr

78 wo targets of thrombin-mediated proteolysis, protease-activated receptor-1 (PAR-1) expressed by strom

79 Protease-activated receptor-1 (PAR-1) is a key player in

80 Protease-activated receptor-1 (PAR-1) was localized to a

81 eceptor for thrombin on endothelial cells is protease-activated receptor-1 (PAR-1), a member of the G

82 The thrombin receptor, protease-activated receptor-1 (PAR-1), plays a key role

83 phorylation on serine residues and prevented protease-activated receptor-1 (PAR-1)-induced Ca(2+) ent

84 c kidney 293 cells through the activation of protease-activated receptor-1 (PAR-1).

85 tes is mediated by proteolytic activation of protease-activated receptor-1 (PAR-1).

86 The thrombin receptor [protease-activated receptor-1 (PAR-1)] is overexpressed

87 signaling function of aPC, mediated through protease-activated receptor-1 (PAR1) and endothelial pro

88 synthesis in neuronal cells by APC required protease-activated receptor-1 (PAR1) and PAR3, which inh

89 Protease-activated receptor-1 (PAR1) contains five N-lin

90 Protease-activated receptor-1 (PAR1) couples the coagula

91 Protease-activated receptor-1 (PAR1) has been shown to p

92 rect oncogenic activity by signaling through protease-activated receptor-1 (PAR1) in carcinoma cells;

93 lood, Aisiku et al describe a novel class of protease-activated receptor-1 (PAR1) inhibitors that blo

94 Protease-activated receptor-1 (PAR1) is a G protein-coup

95 Protease-activated receptor-1 (PAR1) is a G protein-coup

96 Protease-activated receptor-1 (PAR1) is a G protein-coup

97 Protease-activated receptor-1 (PAR1) is a G protein-coup

98 Protease-activated receptor-1 (PAR1) is a G-protein-coup

99 Protease-activated receptor-1 (PAR1) is a guanine nucleo

100 activation of the G protein-coupled receptor protease-activated receptor-1 (PAR1) is an important sti

101 and thermodynamic parameters for individual protease-activated receptor-1 (PAR1) molecules in the ab

102 We show that platelet MMP-1 activates protease-activated receptor-1 (PAR1) on the surface of p

103 Contrary to this view, we show that protease-activated receptor-1 (PAR1) promotes contrastin

104 llular (i3) loop agonist, pepducin, based on protease-activated receptor-1 (PAR1) was solved by NMR a

105 This is exemplified by protease-activated receptor-1 (PAR1), a G protein-couple

106 Signaling by protease-activated receptor-1 (PAR1), a G protein-couple

107 Protease-activated receptor-1 (PAR1), a GPCR activated b

108 tein ALIX regulates lysosomal degradation of protease-activated receptor-1 (PAR1), a GPCR for thrombi

109 d facilitated APC cleavage and activation of protease-activated receptor-1 (PAR1), leading to enhance

110 sition and activates human platelets through protease-activated receptor-1 (PAR1).

111 ar cell recruitment in vivo was dependent on protease-activated receptor-1 activation of the MEK/ERK/

112 of thrombin was attenuated by application of protease-activated receptor-1 and protein kinase C antag

113 The beneficial effects of protease-activated receptor-1 antagonism on limb vascula

114 Atopaxar is a reversible protease-activated receptor-1 antagonist that interferes

115 This study evaluated effects of protease-activated receptor-1 antagonist vorapaxar (Merc

116 elets by alternate mechanisms, including the protease-activated receptor-1 antagonist vorapaxar, have

117 ty and safety of SCH 530348-an oral platelet protease-activated receptor-1 antagonist.

118 itor leupeptin or two structurally different protease-activated receptor-1 antagonists (SCH79797 and

119 Atopaxar (E5555) is a reversible protease-activated receptor-1 thrombin receptor antagoni

120 llebrand factor aptamers, thrombin receptor (protease-activated receptor-1) antagonists, and thrombox

121 ing the thrombin-activatable receptor PAR-1 (protease-activated receptor-1), in Runx1/Cbfb-deleted ML

122 or, low-density lipoprotein-related protein, protease-activated receptor-1, or matrix metalloproteina

123 EGF receptor (EGFR) and a thrombin receptor (protease-activated receptor-1, PAR-1) increases the expr

124 Vorapaxar is a novel antagonist of protease-activated receptor-1, the primary receptor for

125 thermore, MMP-1 induced vasoconstriction via protease-activated receptor-1, whose expression was sign

126 ities via endothelial protein C receptor and protease-activated receptor-1.

127 mplex in response to signals transduced from protease-activated receptor-1.

128 pression of Card10 mRNA and protein, but not protease-activated receptor-1.

129 is externalized via calcium mobilization and protease-activated receptors-1 and -4, and 48% is contai

130 ected protective mechanisms, mediated by the protease activated receptor 2 and heat shock protein 70,

131 erated during injury and inflammation cleave protease-activated receptor 2 (PAR(2)) on primary sensor

132 Protease-activated receptor 2 (PAR(2)), a receptor for i

133 ubiquitinates the G protein-coupled receptor protease-activated receptor 2 (PAR(2)), which is require

134 Protease-activated receptor 2 (PAR-2), a receptor for tr

135 neutrophils, T lymphocytes, mast cells, and protease-activated receptor 2 (PAR-2).

136 odels, we identified the interaction between protease-activated receptor 2 (PAR2) and serine protease

137 A protease-activated receptor 2 (PAR2) antagonist and PAR2

138 lation, and the EPCR-dependent activation of protease-activated receptor 2 (PAR2) by the ternary TF-V

139 Protease-activated receptor 2 (PAR2) is a G protein-coup

140 which regulates liver TICs through the CTSS/protease-activated receptor 2 (PAR2) loop.

141 The G-protein-coupled protease-activated receptor 2 (PAR2) plays an important

142 Protease-activated receptor 2 (PAR2) signaling and downs

143 d scaffold of coagulation proteases cleaving protease-activated receptor 2 (PAR2) that plays pivotal

144 F) conditions induced KLK5 and activated the protease-activated receptor 2 (PAR2), resulting in thymi

145 gulation factor VIIa-dependent activation of protease-activated receptor 2 (PAR2).

146 avage of a G-protein coupled receptor called protease-activated receptor 2 (PAR2).

147 g proinflammatory cytokine secretion through protease-activated receptor 2 (PAR2).

148 Protease-activated receptor 2 activates airway apical me

149 We also provide molecular evidence that protease-activated receptor 2 activation followed by PI3

150 Der p1 activates protease-activated receptor 2 and induces the release of

151 nization of the skin could be blocked by the protease-activated receptor 2 antagonist ENMD-1068.

152 regulate PKA activity in cardiomyocytes via protease-activated receptor 2 proteolysis.

153 Furthermore, we show that protease-activated receptor 2 signaling is involved in m

154 onditions induced kallikrein 5 and activated protease-activated receptor 2, resulting in thymic strom

155 ficantly reduced in STAT6-deficient, but not protease-activated receptor 2-deficient mice.

156 er dysfunction, itch, and dermatitis via the protease-activated receptor 2-thymic stromal lymphopoiet

157 nduces A549 IL-8 secretion via activation of protease-activated receptor 2.

158 ydroxytryptamine [5-HT]), histamine, SLIGRL (protease-activated receptors 2/mas-related G-protein-cou

159 her protease activated receptor-1 (PAR-1) or protease activated receptor-2 (PAR-2) on nonhematopoieti

160 sm that was dependent upon the activation of protease activated receptor-2 and adenosine triphosphate

161 tivation of two Galpha(q)-coupled receptors, protease-activated receptor-2 (PAR(2)) and neurokinin-1

162 Proteases that cleave protease-activated receptor-2 (PAR(2)) at Arg(36) downwa

163 Protease-activated receptor-2 (PAR(2)) is a G-protein co

164 Protease-activated receptor-2 (PAR(2)) is one of four pr

165 Protease-activated receptor-2 (PAR-2) mediates pro-infla

166 The G protein-coupled receptor protease-activated receptor-2 (PAR-2) plays a key role i

167 rthermore, matriptase elicited signaling via protease-activated receptor-2 (PAR-2), and promoted fibr

168 ombosis and activates cell signaling through protease-activated receptor-2 (PAR-2).

169 include serotonin (5-HT) and agonists of the protease-activated receptor-2 (PAR-2).

170 in turn cleaved the pericellular substrates protease-activated receptor-2 (PAR2) and pro-urokinase.

171 uch as trypsin and mast cell tryptase cleave protease-activated receptor-2 (PAR2) at R(36) downward a

172 This study sought to evaluate the role of protease-activated receptor-2 (PAR2) in coxsackievirus B

173 Protease-activated receptor-2 (PAR2) is an emerging new

174 at degrades elastic fibers and activates the protease-activated receptor-2 (PAR2) on endothelial cell

175 Protease-activated receptor-2 (PAR2) traffics to lysosom

176 Protease-activated receptor-2 (PAR2), a cell surface rec

177 type 2 innate lymphoid cells, which required protease-activated receptor-2 expression.

178 e dependent on subtilisin protease activity, protease-activated receptor-2, IL-33R ST2, and MyD88 sig

179 imental arthritis model was not dependent on protease-activated receptor-2, it was dependent on the c

180 The mechanism involved epithelial protease-activated receptor-2-dependent production of le

181 ates nociceptors to induce visceral pain via protease-activated receptor-2.

182 ic nociceptors, which required expression of protease-activated receptor-2.

183 on of beta2-adrenergic receptor (beta2AR) or Protease-activated-receptor-2 (PAR2) results in relief f

184 isms for these contrasting cellular effects, protease activated receptor 3 (PAR3) activation by APC a

185 ptors endothelial protein C receptor (EPCR), protease-activated receptor 3 (PAR3), and macrophage-1 a

186 ed injury depended upon interactions between protease-activated receptor 3 and protease-activated rec

187 hrombin-dependent interactions between human protease-activated receptor 3 and protease-activated rec

188 el, including protease activated receptor-1, protease activated receptor-3, platelet activating facto

189 versible fibrinogen binding in response to a protease activated receptor 4 (PAR4) thrombin receptor a

190 mice lacking the platelet thrombin receptor, protease activated receptor 4 (PAR4; Par4(-/-)), or its

191 sed to arachidonic acid, collagen, U46619 or protease activated receptor 4 activating peptide.

192 P4pal-10 is a protease activated receptor 4-derived pepducin that exhi

193 s platelet and endothelial cell function via protease-activated receptor 4 (PAR-4).

194 Here we show that the thrombin receptor protease-activated receptor 4 agonist peptide AYPGKF eli

195 etween rat protease-activated receptor 1 and protease-activated receptor 4 in cultured podocytes.

196 ns between protease-activated receptor 3 and protease-activated receptor 4 in human podocytes, and be

197 nd between protease-activated receptor 1 and protease-activated receptor 4 in rat podocytes.

198 ncreased platelet responses on activation of protease-activated receptor 4 thrombin receptors noted i

199 Activating protease-activated receptor 4, a platelet receptor for t

200 ing Gbeta1) in murine megakaryocytes reduced protease-activated receptor 4, activating peptide-induce

201 ween human protease-activated receptor 3 and protease-activated receptor 4, and between rat protease-

202 other antiplatelet compounds (antagonists of protease-activated receptor 4, MRS 2179, and clopidogrel

203 Activation with protease-activated receptor 4- activating peptide, the m

204 ur previous study, surface modification with protease-activated receptor 4-activating peptide (PAR4-A

205 reased soluble fibrinogen binding induced by protease-activated receptor 4-activating peptide.

206 Inhibition of protease-activated receptor-4 (PAR-4), but not PAR-2, bl

207 In platelets and other cell types, protease-activated receptor-4 (PAR4) has been shown to d

208 Protease-activated receptor-4 (PAR4) is a G protein-coup

209 ts in blood from mice lacking cathepsin G or protease-activated receptor-4 (PAR4), indicating that ca

210 that suppress excitability via activation of protease-activated receptor-4.

211 This effect is independent of protease-activated receptor activation but requires prot

212 human astrocytoma cells stimulated with the protease-activated receptor agonist thrombin.

213 Stimulation of washed human platelets with protease-activated receptor agonists caused translocatio

214 cates to the membrane after stimulation with protease-activated receptor agonists in a Gq-dependent m

215 opportunities for drug development at other protease activated receptors and across GPCRs.

216 d expand the relationship between proteases, protease-activated receptors, and itch.

217 can cleave a number of substrates, including protease-activated receptors, and may play an important

218 ith the endothelial cell protein C receptor, protease-activated receptors, and other receptors to exe

219 Protease-activated receptors are important targets for d

220 f other GPCRs, such as the ADP receptors and protease-activated receptors, can also potentiate CLEC-2

221 n contrast to its activation of conventional protease-activated receptors, cathepsin S-mediated activ

222 gand, coagulation factor VIIa, TF influences protease-activated receptor-dependent tumor cell behavio

223 eceptors such as the Toll-like receptors and protease-activated receptors, endogenous proteins with p

224 ping revealed that rat podocytes express the protease-activated receptor family of coagulation recept

225 Protease-activated receptors have been implicated as the

226 e proteases, serine protease inhibitors, and protease-activated receptors have been intensively inves

227 ad no effect on the Ca(2+) signals evoked by protease-activated receptors, heterologously expressed m

228 Thrombin, via its protease-activated receptors, is postulated to activate

229 bin potently activates platelets through the protease-activated receptor PAR-1.

230 It is now well accepted that protease activated receptor (PAR) 1 and PAR4 have differ

231 ell protein C receptor (EPCR) and subsequent protease activated receptor (PAR)-1 activation.

232 The involvement of protease activated receptor (PAR)-2 was evaluated using

233 is was not seen in platelets stimulated by a protease activated receptor (PAR)-4 peptide, which is un

234 progression through cell signaling involving protease activated receptor (PAR)2.

235 atelet aggregation to arachidonic acid, ADP, protease-activated receptor (PAR) 1 activation peptide (

236 e the endothelial protein C receptor (EPCR), protease-activated receptor (PAR) 1, and PAR3.

237 which thrombin contributes via activation of protease-activated receptor (PAR) 1.

238 ism dependent on the major thrombin receptor protease-activated receptor (PAR) 1.

239 of the collagen glycoprotein VI and thrombin protease-activated receptor (PAR) 1.

240 Protease-activated receptor (PAR) 2 is a G-protein-coupl

241 ain directly activated naive T cells through protease-activated receptor (PAR) 2 to initiate a chemok

242 The protease-activated receptor (PAR) agonist thrombin elici

243 a is activated by glycoprotein VI (GPVI) and protease-activated receptor (PAR) agonists, but not by a

244 Protease-activated receptor (PAR) signaling is closely l

245 n of coagulation proteases and activation of protease-activated receptor (PAR)-1 and PAR-2.

246 uman platelets express 2 thrombin receptors: protease-activated receptor (PAR)-1 and PAR4.

247 sent study we investigated the importance of protease-activated receptor (PAR)-2 and its ligand mast

248 In this study, we examined the protease-activated receptor (PAR)-2, a GPCR previously s

249 Protease-activated receptor (PAR)-2, Toll-like receptor

250 protease-sensing G protein-coupled receptor, protease-activated receptor (PAR)-2; TSLP induction by p

251 following i.d. 5-HT (5-hydroxytryptamine), a protease-activated receptor (PAR)-4 agonist, and an Mrgp

252 lood, Miyakawa et al show that platelets and protease-activated receptor (PAR)-4 contribute to acetam

253 et accumulation were reduced in mice lacking protease-activated receptor (PAR)-4, which mediates thro

254 botic disorders, we compared the efficacy of protease-activated receptor (PAR)1 and PAR4 in the gener

255 ow provide evidence that C4a is a ligand for protease-activated receptor (PAR)1 and PAR4.

256 Specifically, protease-activated receptors (PAR) 1 and 2, responsive t

257 With the recent interest of protease-activated receptors (PAR) 1 and PAR4 as possibl

258 The G protein-coupled protease-activated receptors (PAR) are key signaling com

259 FXa signalling via activation of protease-activated receptors (PAR) leads to increased in

260 ble of initiating clotting in vitro, and had protease-activated receptors (PAR)-1, -2, and -4.

261 We now demonstrate that protease-activated-receptor (PAR) agonists also stimulat

262 synthetic peptides and pepducins to describe protease-activated receptor PAR1 and PAR4 signaling.

263 The case of the protease-activated receptor PAR1 is particularly relevan

264 (m) values for the hydrolysis of fibrinogen, protease-activated receptor PAR1, and protein C that spa

265 mediator thrombin proteolytically activates protease-activated receptor (PAR1) eliciting a transient

266 The protease-activated receptors (PAR1 and PAR2) are unusual

267 atomic force microscopy (AFM) to image human protease-activated receptors (PAR1) in the functionally

268 y be caused by thrombin acting on astrocytic protease-activated receptors (PAR1) in the hindbrain.

269 GPCRs and other membrane proteins, including protease-activated receptors (PAR1, PAR2, and PAR4), che

270 h as the epithelial sodium channel ENaC, the protease-activated receptor PAR2, the tight junction pro

271 naria exposure appeared to be independent of protease-activated receptor (PAR2) stimulation.

272 ng the proteolytic activity of allergens via protease-activated receptors (PAR2) to initiate inflamma

273 cate that TF signaling via G protein-coupled protease-activated receptors (PAR2, PAR1) additionally d

274 cts appeared to be mediated through specific protease activated receptors (PARs) and sphingosine-1-ph

275 Once activated, protease activated receptors (PARs) are essential in reg

276 likrein directly activates G protein-coupled protease-activated receptors (PARs) 1 and 2, which posse

277 Here we report that stimulation of protease-activated receptors (PARs) activates YAP/TAZ by

278 sed in platelets and activated downstream of protease-activated receptors (PARs) and glycoprotein VI

279 Protease-activated receptors (PARs) are a family of G-pr

280 Protease-activated receptors (PARs) are a family of seve

281 Protease-activated receptors (PARs) are G protein-couple

282 Protease-activated receptors (PARs) are G protein-couple

283 Protease-activated receptors (PARs) are G-protein-couple

284 Protease-activated receptors (PARs) are G-protein-couple

285 Endothelial protease-activated receptors (PARs) are potential serine

286 Protease-activated receptors (PARs) can activate HSCs th

287 The nature of protease-activated receptors (PARs) capable of activatin

288 e protease-mediated activation of epithelial protease-activated receptors (PARs) has been shown to in

289 Expression of protease-activated receptors (PARs) mRNA was detected in

290 mation through the proteolytic activation of protease-activated receptors (PARs), fibrinogen, factor

291 Coagulation proteases activate protease-activated receptors (PARs).

292 oprotein Ibalpha (GpIbalpha) and cleavage of protease-activated receptors (PARs).

293 and exerts profibrotic effects by activating protease-activated receptors (PARs).

294 iple physiologically important responses via protease-activated receptors (PARs).

295 we examined the roles of thrombin receptors (protease-activated receptors, PARs) and the ADP receptor

296 Together, our results suggest a role for protease-activated receptor signaling in neural tube clo

297 ulation-activated osteopontin, chemerin, and protease-activated receptor signaling, as well as platel

298 thrombin contributes to podocyte injury in a protease-activated receptor-specific manner during nephr

299 o-l-arginine methyl ester (100 mumol/L) or a protease-activated receptor type 1 blocker (BMS 200261,

300 otype among an unusual group of GPCRs called protease activated receptors, which self-activate after